Cardiovascular Disease Protection Tissue

Completed

Conditions studied: Myocardial Ischemia

In brief

Recent evidence of a potential role for cardiac progenitor cells (CPCs) in cardiac repair and the discovery of a vasoprotective axis of the renin-angiotensin system (RAS) offer such breakthroughs. Investigators have observed that an imbalance in the vasoprotective axis {angiotensin converting enzyme 2 (ACE2)/angiotensin-(1-7) \[Ang-(1-7)\]/Mas receptor} and the vasodeleterious axis \[angiotensin converting enzyme (ACE)/angiotensin II (AngII)/AngII type 1 receptor (AT1R)\] of the RAS within the CPCs affects their functionality and regenerative potential. Investigators believe that restoring the balance between these two axes of the RAS is essential to improve CPC function and enhance their reparative capabilities. These observations have led to the hypothesis that genetic modification of CPCs by overexpression of ACE2/Ang-(1-7) will enhance their reparative function and improve their potential to attenuate myocardial ischemia-induced cardiac damage.

Key facts

Study ID

NCT02348515

Run by

University of Florida

People needed

8

Starts

2013-06-01

Expected to finish

2018-09-28

Last updated by the study team

2018-11-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• heart transplant surgery
• left ventricular assist device implantation
• heart surgery required for atrial fibrillation and right atria cannulation

You may not qualify if…

• We are collecting discarded tissues following surgery. There is no exclusion criteria for this study.

Where it is running

• Yanfei Qi — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.